Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
OLMESART AMLODIPINE GPPL, OLMESART AMLODIPINE, OLMEKAR, OLMESATAN AMLODIPINE GPPL, OLMESATAN AMLO, OLMESART AMLODIPINE (Generic Partners Pty Ltd)
Product name
OLMESART AMLODIPINE GPPL, OLMESART AMLODIPINE, OLMEKAR, OLMESATAN AMLODIPINE GPPL, OLMESATAN AMLO, OLMESART AMLODIPINE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
188 working days (255)
Active ingredients
Amlodipine besilate; Olmesartan medoxomil
Registration type
New generic medicine
Indication
OLMESART AMLODIPINE GPPL, OLMESART AMLODIPINE, OLMEKAR, OLMESATAN AMLODIPINE GPPL, OLMESATAN AMLO, OLMESART AMLODIPINE (tablets) is indicated for the treatment of hypertension. Treatment should not be initiated with this fixed-dose combination.